Publications by authors named "M A Breidenbach"

Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults suffering from relapsed/refractory B-lineage acute lymphoblastic leukemia. Bridging therapy is used to control disease prior to start of lymphodepletion before CAR infusion and thereby improve efficacy of CAR therapy. However, the effect of different bridging strategies on outcome, side effects and response to CAR therapy is still poorly understood.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists are working on new cancer treatments called immunotherapies, especially using CAR T cells, which have shown great results for kids with a type of leukemia.
  • When kids' leukemia comes back or doesn’t respond to regular treatments, they need a different kind of temporary treatment called bridging therapy before getting CAR T cells.
  • A group of doctors in Europe is trying to create guidelines for this bridging therapy to make sure it’s more effective and consistent for all kids with this kind of cancer.
View Article and Find Full Text PDF

CAREPATH project is focusing on providing an integrated solution for sustainable care for multimorbid elderly patients with dementia or mild cognitive impairment. The project has a digitally enhanced integrated patient-centered care approach clinical decision and associated intelligent tools with the aim to increase patients' independence, quality of life and intrinsic capacity. In this paper, the conceptual aspects of the CAREPATH project, in terms of technical and clinical requirements and considerations, are presented.

View Article and Find Full Text PDF

Background: The COVID-19 pandemic has demonstrated the possibility of severe ventilator shortages in the near future.

Objective: We aimed to develop an acute shortage ventilator.

Methods: The ventilator was designed to mechanically compress a self-inflating bag resuscitator, using a modified ventilator patient circuit, which is controlled by a microcontroller and an optional laptop.

View Article and Find Full Text PDF

We report on a comparison between the theoretically predicted and experimentally measured spectra of the first-forbidden nonunique β-decay transition ^{137}Xe(7/2^{-})→^{137}Cs(7/2^{+}). The experimental data were acquired by the EXO-200 experiment during a deployment of an AmBe neutron source. The ultralow background environment of EXO-200, together with dedicated source deployment and analysis procedures, allowed for collection of a pure sample of the decays, with an estimated signal to background ratio of more than 99 to 1 in the energy range from 1075 to 4175 keV.

View Article and Find Full Text PDF